In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5

Molecular Immunology

Volumn 32, Issue 16, 1995, Pages 1183-1195

  Evans, Mark J ^a   Rollins, Scott A ^a   Wolff, Dennis W ^a   Rother, Russell P ^a   Norin, Allen J ^b   Therrien, Denise M ^a   Grijalva, Galo A ^b   Mueller, John P ^a   Nye, Steven H ^a   Squinto, Stephen P ^a   Wilkins, James A ^a  

^a ALEXION PHARMACEUTICALS   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

C5; complement; rhesus monkey; scFv; single chain antibody

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; IMMUNOGLOBULIN FV FRAGMENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; HEART INJURY; HEART PERFUSION; HEMOLYSIS; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MOLECULAR CLONING; MONKEY; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BLOOD PRESSURE; COMPLEMENT ACTIVATION; COMPLEMENT C5; HEART RATE; HEMOLYSIS; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MACACA MULATTA; MICE; MOLECULAR SEQUENCE DATA; MYOCARDIUM; PERFUSION; RECOMBINANT PROTEINS;

ANIMALIA; BACTERIA (MICROORGANISMS); GALLUS GALLUS; MACACA MULATTA; MAMMALIA;

EID: 0029587541     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/0161-5890(95)00099-2     Document Type: Article

References (50)

1. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6
2. Single chain antigen-binding proteins
3. Epstein-Barr virus-derived vectors for transient and stable expression of recombinant proteins
4. C5 gene influences the development of murine myasthenia gravis
5. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
6. 2, and Fab′ in mice
7. Inhibition of neutrophil adhesion reduces myocardial infarct size
8. The membrane attack complex of complement at the endplate in myasthenia gravis
9. Rapid expression of an anti-human C5 chimeiric Fab utilizing a vector that replicates in COS and 293 cells
10. C5a anaphyloatoxin and its seven transmembrane-segment receptor
11. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass
12. Human anti-self antibodies with high specificity from phage display libraries
13. Somatic mutatio creates diversity in the major group of mouse immunoglobulin κ light chains
14. Evolution of human immunoglobulin κ J region genes
15. Complement activation and inhibition in myocardial ischemia and reperfusion injury
16. Effects of complement activation in the isolated heart. Role of the terminal complement components
17. Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium
18. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli
19. Human immune response to monoclonal antibodies
20. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II Pharmacokinetics and immune response
21. Mouse variable-region gene families complexity polymorphism and use in non-autoimmune responses
22. Recombinant anti-sialidase single-chain variable fragment antibody. Characterization, formation of dimer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex
23. The control of homologous lysis
24. Purification of native proteins from the cytoplasm and periplasm of Escherichia coli using IMAC and histidine tails: a comparison of proteins and protocols
25. The complement system
26. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response
27. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49
28. Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma
29. Complement inhibition may attenuate acute lung injury after cardiopulmonary bypass in pigs
30. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis
31. The effects of complement activation curing cardiopulmonary bypass
32. Complement and infectious diseases
33. Clinical complementology: recent progress and future trends
34. Protective effects of soluble CR1 in complement-and neutrophil-mediated tissue injury
35. Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli.
36. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle
37. Metabolism of complement factor D in renal failure
38. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation
39. Two types of somatic recombination are necessary for the generation of complete immunoglobulin heavy-chain genes
40. Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium
41. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma
42. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion
43. Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730)
44. Use of T7 RNA polymerase to direct expression of cloned genes
45. Complement activation during extracorporeal circulation: in vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits
46. Rhenium-186-labeled chimeric antibody NR-LU-13: pharmacokinetics, biodistribution and immunogenicity relative to murine analog NR-LU-10
47. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis
48. Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies
49. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
50. Structure of a single-chain antibody variable domain (Fv) fragment complexed with a carbohydrate antigen at 1.7-A resolution